Charles Schwab Investment Management Inc. Purchases Shares of 23,850 Abeona Therapeutics Inc (NASDAQ:ABEO)

Charles Schwab Investment Management Inc. purchased a new stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 23,850 shares of the biopharmaceutical company’s stock, valued at approximately $151,000. Charles Schwab Investment Management Inc. owned about 0.06% of Abeona Therapeutics as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. GSA Capital Partners LLP grew its position in Abeona Therapeutics by 54.3% during the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 33,831 shares during the period. Rosalind Advisors Inc. increased its stake in shares of Abeona Therapeutics by 4.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after purchasing an additional 82,000 shares in the last quarter. abrdn plc increased its stake in shares of Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock worth $2,067,000 after purchasing an additional 200,647 shares in the last quarter. Simplify Asset Management Inc. purchased a new stake in shares of Abeona Therapeutics in the 2nd quarter worth $1,732,000. Finally, Renaissance Technologies LLC raised its holdings in Abeona Therapeutics by 581.6% in the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after purchasing an additional 429,456 shares during the period. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Price Performance

Shares of Abeona Therapeutics stock opened at $5.63 on Friday. The company has a market capitalization of $244.74 million, a price-to-earnings ratio of -2.09 and a beta of 1.44. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The stock’s 50-day simple moving average is $6.20 and its 200-day simple moving average is $5.51. Abeona Therapeutics Inc has a 52 week low of $3.05 and a 52 week high of $9.01.

Analyst Upgrades and Downgrades

ABEO has been the subject of a number of analyst reports. StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, December 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Monday, November 25th.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.